サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655486

乳がん治療薬の世界市場

Breast Cancer Therapeutics

出版日
ページ情報
英文 372 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
乳がん治療薬の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 372 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

乳がん治療薬の世界市場は2030年までに904億米ドルに達する見込み

2024年に451億米ドルと推定された乳がん治療薬の世界市場は、2024～2030年の分析期間においてCAGR 12.3%で成長し、2030年には904億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 12.6％を記録し、分析期間終了までに749億米ドルに達すると予測されます。化学療法分野の成長率は、分析期間のCAGRで11.0％と推定されます。

米国市場は115億米ドルと推定、中国はCAGR16.2%で成長予測

米国の乳がん治療薬市場は、2024年に115億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに219億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.1%と10.0%と予測されています。欧州では、ドイツがCAGR約9.1%で成長すると予測されています。

世界の乳がん治療薬市場動向と促進要因

現代の乳がん治療薬の構成要素と治療への影響とは？

乳がん治療薬は、乳がん細胞を標的とし、除去するためにデザインされた幅広い治療法を包含します。これらの治療には、ホルモン療法、化学療法、分子標的治療、そして最近では免疫療法が含まれます。ホルモン療法は、体内でホルモンを産生する能力を阻害したり、乳がん細胞に対するホルモンの作用を阻害することで、ホルモン受容体陽性の乳がんを標的とします。化学療法は、腫瘍を縮小させるための手術前（ネオアジュバント療法）、または残存するがん細胞を破壊するための手術後（アジュバント療法）に使用され、依然として基本的な治療法です。標的療法と免疫療法は、乳がんの増殖と転移に関連する分子経路を特異的に標的とする新しい薬剤クラス別です。これらの治療法の進化により、乳がん患者の生存率とQOLは大幅に改善され、個別化医療は腫瘍学において達成可能な目標となっています。

技術の進歩は乳がん治療にどのような影響を与えているか？

技術の進歩は、乳がん治療の状況を劇的に変化させています。例えば、ゲノム検査技術の開発により、個々のがんの特徴をより正確に特定することが可能になり、各患者に最も効果が期待できる治療法の選択が導かれるようになった。プレシジョン・メディシン（精密医療）として知られるこのアプローチは、個々の遺伝子プロファイルに合わせて治療を調整し、副作用を最小限に抑えながら治療効果を高める。さらに、画像診断や手術技術の進歩により、周囲の健康な組織をできる限り温存しながら腫瘍を発見し、完全に切除することができるようになった。診断プロセスにおける人工知能の統合もまた、乳がん診断の精度とスピードを高め、早期かつ確実な発見をサポートすることを約束しています。

乳がん治療薬の新たな動向とは？

乳がん治療薬の新たな動向には、より低侵襲で的を絞った治療法へのシフトが含まれます。ホルモン療法に反応しないサブタイプであるトリプルネガティブ乳がんを治療するためのPARP阻害剤の開発への関心が高まっています。ホルモン受容体陽性乳がんにおけるCDK4/6阻害剤の使用もまた、進行がん患者に新たな希望をもたらす動向です。さらに、生存期間の延長だけでなく、治療に関連する副作用を軽減することでQOLを向上させる治療法の開発にもますます注目が集まっています。また、2種類以上の薬剤を使用してがん細胞を異なる方法で攻撃する併用療法の動向も、単剤治療に対する耐性を克服する新たな方法を提供するものとして注目を集めています。

乳がん治療薬市場の成長を促すものは何か？

乳がん治療薬市場の成長は、世界の乳がんの有病率の上昇、効果的な治療に対する需要の増加など、いくつかの要因によってもたらされます。また、新規創薬ターゲットや治療レジメンの発見につながるがん研究の進歩も、市場拡大に大きく寄与しています。さらに、認知度の向上と検診プログラムによって早期診断が可能になり、早期治療や治癒の可能性のある治療の対象となる患者数が増加しています。ヘルスケア適用範囲の拡大と世界の医療支出の増加は、これらの治療へのアクセス拡大を可能にし、市場の成長を支えています。さらに、臨床試験中の乳がん治療薬の強力なパイプラインは、治療選択肢の継続的な改善と拡大を約束し、この分野への継続的な投資と関心を確実なものにしています。これらの力学は、医療ニーズと技術革新の両方が市場を牽引していることを強調し、腫瘍学分野における市場の重要性を浮き彫りにしています。

セグメント

治療（標的療法、化学療法、ホルモン療法、免疫療法）

調査対象企業の例（注目の26社）

  • AstraZeneca PLC
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Roche Diagnostics
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-1553

Global Breast Cancer Therapeutics Market to Reach US$90.4 Billion by 2030

The global market for Breast Cancer Therapeutics estimated at US$45.1 Billion in the year 2024, is expected to reach US$90.4 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 12.6% CAGR and reach US$74.9 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 11.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.5 Billion While China is Forecast to Grow at 16.2% CAGR

The Breast Cancer Therapeutics market in the U.S. is estimated at US$11.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$21.9 Billion by the year 2030 trailing a CAGR of 16.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.1% and 10.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR.

Global Breast Cancer Therapeutics Market - Key Trends & Drivers Summarized

What Constitutes Modern Breast Cancer Therapeutics and Their Impact on Treatment?

Breast cancer therapeutics encompass a wide range of medical treatments designed to target and eliminate breast cancer cells. These treatments include hormonal therapies, chemotherapy, targeted therapy, and increasingly, immunotherapy. Hormonal therapies target hormone-receptor-positive breast cancers by blocking the body’s ability to produce hormones or by interfering with the effects of hormones on breast cancer cells. Chemotherapy remains a cornerstone treatment, used either before surgery (neoadjuvant therapy) to shrink tumors or after (adjuvant therapy) to destroy any remaining cancerous cells. Targeted therapies and immunotherapies represent a newer class of drugs that specifically target molecular pathways associated with breast cancer growth and spread. The evolution of these treatments has significantly improved survival rates and quality of life for breast cancer patients, making personalized medicine an achievable goal in oncology.

How Are Technological Advancements Influencing Breast Cancer Treatment?

Technological advancements are drastically reshaping the landscape of breast cancer treatment. The development of genomic testing technologies, for example, allows for more precise identification of individual cancer characteristics, guiding the selection of therapies that are most likely to be effective for each patient. This approach, known as precision medicine, tailors treatment to individual genetic profiles, enhancing treatment efficacy while minimizing side effects. Furthermore, advancements in imaging and surgical techniques have improved the detection and complete removal of tumors while preserving as much of the surrounding healthy tissue as possible. The integration of artificial intelligence in diagnostic processes also promises to enhance the accuracy and speed of breast cancer diagnostics, supporting early and reliable detection.

What Are the Emerging Trends in Breast Cancer Therapeutics?

Emerging trends in breast cancer therapeutics include a shift towards less invasive and more targeted treatment options. There is growing interest in the development of PARP inhibitors for treating triple-negative breast cancer, a subtype that does not respond to hormonal therapies. The use of CDK4/6 inhibitors in hormone receptor-positive breast cancer is another trend, offering new hope for patients with advanced cancer. Additionally, there is an increasing focus on developing therapies that provide not only longer survival but also better quality of life by reducing treatment-related side effects. The trend towards combination therapies, which use two or more drugs to attack cancer cells in different ways, is also gaining traction, offering new ways to overcome resistance to single-drug treatments.

What Drives the Growth of the Breast Cancer Therapeutics Market?

The growth in the breast cancer therapeutics market is driven by several factors, including the rising prevalence of breast cancer globally, which increases the demand for effective treatments. Advances in cancer research that lead to the discovery of novel drug targets and treatment regimens also contribute significantly to the expansion of the market. Furthermore, growing awareness and screening programs have led to earlier diagnosis, increasing the number of patients eligible for early-stage and potentially curative therapies. The expansion of healthcare coverage and increased healthcare spending globally enable greater access to these treatments, supporting market growth. Moreover, the strong pipeline of breast cancer drugs in clinical trials promises continuous improvement and expansion of treatment options, ensuring ongoing investment and interest in the sector. These dynamics underscore a market driven by both medical need and innovation, highlighting its critical importance in the field of oncology.

SCOPE OF STUDY:

The report analyzes the Breast Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Targeted Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 26 Featured) -

  • AstraZeneca PLC
  • Celgene Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Novartis International AG
  • Pfizer, Inc.
  • Roche Diagnostics
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Breast Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Oncology Research Propel Growth in Breast Cancer Therapeutics Market
    • Increasing Incidence of Breast Cancer Expands Addressable Market Opportunity
    • Technological Innovations in Targeted Therapies Generate Demand for Advanced Treatments
    • Growth in Personalized Medicine Drives Adoption of Breast Cancer Therapeutics
    • Rising Awareness and Early Detection Strengthens Business Case for Therapeutic Solutions
    • Adoption of Immunotherapies Spurs Growth in Breast Cancer Treatment
    • Impact of Genetic Testing and Biomarkers Expands the Market for Personalized Therapies
    • Demand for Minimally Invasive Treatments Generates Opportunities for Innovation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Breast Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Breast Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: USA 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: Canada 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • JAPAN
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Japan 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • CHINA
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: China 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • EUROPE
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Europe 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Europe 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • FRANCE
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: France 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • GERMANY
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Germany 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Italy 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: UK 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Spain 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Russia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Rest of Europe 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Australia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • INDIA
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: India 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: South Korea 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Breast Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Latin America 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Latin America 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Argentina 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Brazil 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Mexico 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Latin America 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Breast Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Middle East 15-Year Perspective for Breast Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Middle East 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Iran 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Israel 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Saudi Arabia 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UAE 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Middle East 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030
  • AFRICA
    • Breast Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Breast Cancer Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Africa 15-Year Perspective for Breast Cancer Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Hormonal Therapy and Immunotherapy for the Years 2015, 2025 & 2030

IV. COMPETITION